Reslizumab (a humanized anti-IL-5 monoclonal antibody) therapy significantly improved the asthma and nasal symptoms in patients with eosinophilic asthma associated chronic rhinosinusitis (CRS) with polyps.

CRS with polyps, often combined with asthma, is linked with eosinophilic inflammation. N V Boiko et al. evaluated patients with severe asthma on reslizumab intravenous at a dose of 3 mg/kg once in 4 weeks to study the effectiveness of reslizumab.

Out of nine patients, 7 had CRS with polyps and 2 patients had chronic non-allergic rhinitis (NARES) symptoms. Nasal symptoms via Sino-nasal Outcome Test (SNOT-22); endoscopic image of nose; variations in the Sinus CT of paranasal sinuses via Lund-Mackay scale; total polyp score (TPS); rhinocytogram outcomes; blood eosinophilic cationic protein and eosinophil levels were studied after 6 months. Decrease in asthma attacks, systemic corticosteroids usage, spirometry test results and Asthma Control Test (ACT) were assessed for efficacy of asthma management.

Eight patients showed improvement of nasal symptoms along with noticeable recovery in asthma control. Patients having CRS with polyps had more significantly improved asthma. It was possible to identify anamnestic manifestation of NARES symptoms in the early phases of the disease in these patients.